Sugi Predict

Sugi Predict / Compounds / SCHEMBL792541

SCHEMBL792541

SCHEMBL792541

Cc1ccc2c(c1)N(CC(=O)N1CCCCC1)C(=O)Cn1c-2c(C2CCCCC2)c2ccc(S(=O)(=O)NC(C)(C)C)cc21

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ LMNA P02545 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SCN9A Q15858 1/20 0.35
▸ F10 P00742 6/20 0.34
▸ PARG Q86W56 1/20 0.34
▸ CCKAR P32238 1/20 0.33
▸ CCKBR P32239 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NR1I2 O75469 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792610 0.83 MEN1 (0.38) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL792650 0.81 MEN1 (0.40) ALDH1A1TSHRLMNAMAPTMEN1
SCHEMBL12429173 0.79 PARG (0.36) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL792447 0.78 MEN1 (0.38) ALDH1A1TSHRLMNAMAPTMEN1
SCHEMBL792319 0.78 KMT2A (0.35) ALDH1A1TSHRLMNAMEN1KMT2A
SCHEMBL792897 0.78 SCN9A (0.34) ALDH1A1TSHRLMNAMEN1KMT2A
SCHEMBL14572867 0.78 NR1I2 (0.42) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL792670 0.76 KMT2A (0.34) ALDH1A1TSHRMEN1KMT2ASCN9A
SCHEMBL792903 0.76 PARG (0.35) LMNAMEN1KMT2ASCN9APARG
SCHEMBL792951 0.76 SCN9A (0.39) ALDH1A1LMNAMAPTSCN9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 — — US disclosed
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 — — US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 — — US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 — — US disclosed
EP-2206715-A1 Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor Japan Tobacco, Inc. (JP) 2010-07-14 — — EP disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 — — US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 ALDH1A1 750/4885TSHR 4089/4885LMNA 4323/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 ALDH1A1 750/4885TSHR 4089/4885LMNA 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.